Drug class
Low-molecular-weight heparin (LMWH); anticoagulant and antithrombotic
Mechanism of action
Binds antithrombin and accelerates inhibition of activated coagulation factor Xa, with a lower inhibitory effect on thrombin (factor IIa). Its anti-Xa activity exceeds its anti-IIa activity, as expected for this LMWH.
General use cases
- Prevention and treatment of venous thromboembolic disorders in clinical settings covered by the locally authorised parnaparin product information; exact indication and dosing depend on formulation and jurisdiction.
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
